-
公开(公告)号：US11013722B2
公开(公告)日：2021-05-25
申请号：US16272050
申请日：2019-02-11
申请人： KOWA COMPANY, LTD.
IPC分类号： A61K31/423 , A61K31/397 , A61K45/06
摘要： The present invention addresses the problem of providing a pharmaceutical combination composition and drug combinations for the prevention and/or treatment of dyslipidemic conditions such as atherosclerosis, hypercholesterolemia, low HDL blood disease in mammals including humans. A pharmaceutical composition for the prevention and/or treatment of dyslipidemia, etc. which comprises (a) a compound represented by the general formula (1) (in the formula, each symbol is the same as defined in the specification) or a salt thereof or a solvate thereof and (b) a cholesterol absorption inhibitor.
-
公开(公告)号：US20190030005A1
公开(公告)日：2019-01-31
申请号：US16150514
申请日：2018-10-03
申请人： KOWA COMPANY, LTD.
发明人： Toshiaki Takizawa
IPC分类号： A61K31/423 , A61K31/202 , A61K31/232
摘要： This invention provides a combination-drug composition and a combination use of pharmaceuticals for preventing and/or treating dyslipidemia states, such as hyper-LDL cholesterolemia, in mammals, including humans. This invention pertains to a drug composition for preventing and/or treating dyslipidemia and the like, said drug composition comprising the following: (R)-2-[3-[[N-(benzoxazole-2-yl)-N-3-(4-methoxyphenoxy)propyl] aminomethyl]phenoxy] butyric acid, a salt thereof, or a solvate of either; and an omega-3 fatty acid or an ester derivative of an ω-3 fatty acid.
-
公开(公告)号：US20180185337A1
公开(公告)日：2018-07-05
申请号：US15904922
申请日：2018-02-26
申请人： KOWA COMPANY, LTD.
IPC分类号： A61K31/423 , A61K45/06 , A61K31/397
CPC分类号： A61K31/423 , A61K31/397 , A61K45/06 , A61K2300/00
摘要： The present invention addresses the problem of providing a pharmaceutical combination composition and drug combinations for the prevention and/or treatment of dyslipidemic conditions such as atherosclerosis, hypercholesterolemia, low HDL blood disease in mammals including humans. A pharmaceutical composition for the prevention and/or treatment of dyslipidemia, etc. which comprises (a) a compound represented by the general formula (1) (in the formula, each symbol is the same as defined in the specification) or a salt thereof or a solvate thereof and (b) a cholesterol absorption inhibitor.
-
公开(公告)号：US09931321B2
公开(公告)日：2018-04-03
申请号：US15399856
申请日：2017-01-06
申请人： KOWA COMPANY, LTD.
IPC分类号： A61K31/423 , A61K31/397 , A61K45/06
CPC分类号： A61K31/423 , A61K31/397 , A61K45/06 , A61K2300/00
摘要： The present invention addresses the problem of providing a pharmaceutical combination composition and drug combinations for the prevention and/or treatment of dyslipidemic conditions such as atherosclerosis, hypercholesterolemia, low HDL blood disease in mammals including humans. A pharmaceutical composition for the prevention and/or treatment of dyslipidemia, etc. which comprises (a) a compound represented by the general formula (1) (in the formula, each symbol is the same as defined in the specification) or a salt thereof or a solvate thereof and (b) a cholesterol absorption inhibitor (1).
-
公开(公告)号：US20150196538A1
公开(公告)日：2015-07-16
申请号：US14429449
申请日：2013-09-27
申请人： KOWA COMPANY, LTD.
IPC分类号： A61K31/423 , A61K31/397
CPC分类号： A61K31/423 , A61K31/397 , A61K45/06 , A61K2300/00
摘要： The present invention addresses the problem of providing a pharmaceutical combination composition and drug combinations for the prevention and/or treatment of dyslipidemic conditions such as atherosclerosis, hypercholesterolemia, low HDL blood disease in mammals including humans. A pharmaceutical composition for the prevention and/or treatment of dyslipidemia, etc. which comprises (a) a compound represented by the general formula (1) (in the formula, each symbol is the same as defined in the specification) or a salt thereof or a solvate thereof and (b) a cholesterol absorption inhibitor.
摘要翻译： 本发明涉及提供用于预防和/或治疗诸如动脉粥样硬化，高胆固醇血症，包括人在内的哺乳动物中的低HDL血液病的血脂异常状况的药物组合组合物和药物组合的问题。 一种用于预防和/或治疗血脂异常等的药物组合物，其包含（a）由通式（1）表示的化合物（式中各符号与说明书中所定义的相同）或其盐 或其溶剂合物和（b）胆固醇吸收抑制剂。
-
公开(公告)号：US20170304273A1
公开(公告)日：2017-10-26
申请号：US15513277
申请日：2015-09-28
申请人： KOWA COMPANY, LTD.
发明人： Yuta Inokuchi , Haruki Shibata , Toshiaki Takizawa
IPC分类号： A61K31/423 , A61K31/4152 , A61K45/06 , A61K45/00
CPC分类号： A61K31/423 , A61K31/4152 , A61K31/421 , A61K31/505 , A61K45/00 , A61K45/06 , A61K2300/00
摘要： This invention provides a combination-drug composition and a combination use of pharmaceuticals for preventing and/or treating dyslipidemic conditions such as hyper-LDL cholesterolemia in mammals, including humans.This invention pertains to a drug composition for preventing and/or treating dyslipidemia and the like, the drug composition including the following: (R)-2-[3-[[N-(benzoxazol-2-yl)-N-3-(4-methoxyphenoxy)propyl]aminomethyl]phenoxy] butyric acid, a salt thereof, or a solvate of either; and (S)-trans-{4-[({2-[({1-[3,5-bis(trifluoromethyl)phenyl]ethyl}{5-[2-(methylsulfonyl)ethoxy]pyrimidin-2-yl}amino)methyl]-4-(trifluoromethyl)phenyl}(ethyl)amino)methyl]cyclohexyl} acetic acid, a salt thereof, or a solvate of either.
-
公开(公告)号：US09572798B2
公开(公告)日：2017-02-21
申请号：US14429449
申请日：2013-09-27
申请人： KOWA COMPANY, LTD.
IPC分类号： A61K31/423 , A61K31/397 , A61K45/06
CPC分类号： A61K31/423 , A61K31/397 , A61K45/06 , A61K2300/00
摘要： The present invention addresses the problem of providing a pharmaceutical combination composition and drug combinations for the prevention and/or treatment of dyslipidemic conditions such as atherosclerosis, hypercholesterolemia, low HDL blood disease in mammals including humans. A pharmaceutical composition for the prevention and/or treatment of dyslipidemia, etc. which comprises (a) a compound represented by the general formula (1) (in the formula, each symbol is the same as defined in the specification) or a salt thereof or a solvate thereof and (b) a cholesterol absorption inhibitor.
摘要翻译： 本发明涉及提供用于预防和/或治疗诸如动脉粥样硬化，高胆固醇血症，包括人在内的哺乳动物中的低HDL血液病的血脂异常状况的药物组合组合物和药物组合的问题。 一种用于预防和/或治疗血脂异常等的药物组合物，其包含（a）由通式（1）表示的化合物（式中各符号与说明书中所定义的相同）或其盐 或其溶剂合物和（b）胆固醇吸收抑制剂。
-
公开(公告)号：US20170112811A1
公开(公告)日：2017-04-27
申请号：US15399856
申请日：2017-01-06
申请人： KOWA COMPANY, LTD.
IPC分类号： A61K31/423 , A61K31/397
CPC分类号： A61K31/423 , A61K31/397 , A61K45/06 , A61K2300/00
摘要： The present invention addresses the problem of providing a pharmaceutical combination composition and drug combinations for the prevention and/or treatment of dyslipidemic conditions such as atherosclerosis, hypercholesterolemia, low HDL blood disease in mammals including humans. A pharmaceutical composition for the prevention and/or treatment of dyslipidemia, etc. which comprises (a) a compound represented by the general formula (1) (in the formula, each symbol is the same as defined in the specification) or a salt thereof or a solvate thereof and (b) a cholesterol absorption inhibitor. (1)
-
公开(公告)号：US20200246314A1
公开(公告)日：2020-08-06
申请号：US16853121
申请日：2020-04-20
申请人： KOWA COMPANY, LTD.
发明人： Yuta Inokuchi , Toshiaki Takizawa
IPC分类号： A61K31/423 , A61K31/455
摘要： This invention provides a combination-drug composition and a combination use of pharmaceuticals for preventing and/or treating dyslipidemic conditions such as hyper-LDL cholesterolemia in mammals, including humans. This invention pertains to a drug composition for preventing and/or treating dyslipidemia and the like, the drug composition including the following: (R)-2-[3-[[N-(benzoxazol-2-yl)-N-3-(4-methoxyphenoxy)propyl]aminomethyl]phenoxy] butyric acid, a salt thereof, or a solvate of either; and nicotinic acid and nicotinic-acid amide, collectively referred to as niacin, an ester derivative thereof, a salt thereof, or a solvate of any of these.
-
公开(公告)号：US20190167645A1
公开(公告)日：2019-06-06
申请号：US16272050
申请日：2019-02-11
申请人： KOWA COMPANY, LTD.
IPC分类号： A61K31/423 , A61K45/06 , A61K31/397
摘要： The present invention addresses the problem of providing a pharmaceutical combination composition and drug combinations for the prevention and/or treatment of dyslipidemic conditions such as atherosclerosis, hypercholesterolemia, low HDL blood disease in mammals including humans. A pharmaceutical composition for the prevention and/or treatment of dyslipidemia, etc. which comprises (a) a compound represented by the general formula (1) (in the formula, each symbol is the same as defined in the specification) or a salt thereof or a solvate thereof and (b) a cholesterol absorption inhibitor.
-
-
-
-
-
-
-
-
-
搜索结果
15 条记录 (耗时 0.015 秒)
